Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Congress 2022: Industry Sponsored Satellite Symposia – Breast Cancer, Early Stage

ESMO-Congress-2022-1000x250

Friday 9 September

Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

04-Targeting-HER2-Low-Expression-in-Breast-Cancer-PEERVIEW-ONCOLOGY-thumb

Friday, 10:15 - 11:45
View the satellite invitation

SERDs at the Inflection Point in Pretreated ER+/HER- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes with Novel ER-Targeting Therapies

09-SERDs-at-the-Inflection-Point-in-Pretreated-ER-HER-Breast-Cancer-PEERVIEW-ONCOLOGY-thumb

Friday, 18:00 - 19:30
View the satellite invitation

Saturday 10 September

Improving Outcomes in Patients with High-Risk HR+/HER2- EBC: Keeping the Patient Central

28-Improving-Outcomes-inPatients-with-High-Risk-HR-HER2-EBC-MEDSCAPE-thumb

Saturday, 18:30 - 20:00
View the satellite invitation

Sunday, 11 September

Triple Negative Breast Cancer: An Evolving Treatment Landscape

42-Triple-Negative-Breast-Cancer-An-Evolving-Treatment-Landscape-MSD-Thumb

Sunday, 18:30 - 20:00
View the satellite invitation

Monday 12 September

What, Why and How: Expert Review and Opinions on the Potential of Oral SERDs for Our Patients With HR+ BC

50-What-Why-and-How-ROCHE-Thumb

Monday, 13:00 - 14:30
View the satellite invitation

ER+ / HER2- Breast Cancer: What’s Next for Patients & Providers?

57-ER-HER2-Breast-Cancer-Whats-Next-for-Patients-Providers-thumb

Monday, 18:30 - 20:00
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.